Siemens Healthcare subsidiary PETNet Solutions said it will produce a new investigational molecular biomarker for use in clinical trials on behalf of NuView Life Sciences.
The biomarker, copper-64 (Cu-64) TP3805, targets the vasoactive intestinal peptide 1 (VPAC1) receptor, which is overexpressed on the surface of malignant cells, the company said.
The biomarker is being studied with PET/CT and PET/MRI for prostate and breast cancer. Because of its long half-life of 12.7 hours, Cu-64 TP3805 is better suited than other radiopharmaceuticals for distribution across a wide geographical area for clinical trials.
